Shender Victoria, Arapidi Georgij, Butenko Ivan, Anikanov Nikolay, Ivanova Olga, Govorun Vadim
Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency of the Russian Federation, Malaya Pirogovskaya 1a, Moscow 119435, Russian Federation.
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya str. 16/10, Moscow 117997, Russian Federation.
Data Brief. 2018 Dec 19;22:557-562. doi: 10.1016/j.dib.2018.12.056. eCollection 2019 Feb.
Despite a large number of proteomic studies of biological fluids from ovarian cancer patients, there is a lack of sensitive screening methods in clinical practice (Kim et al., 2016) (DOI:https://doi.org/10.1111/cas.12987[1]). Low molecular weight endogenous peptides more easily diffuse across endothelial barriers than proteins and can be more relevant biomarker candidates (Meo et al., 2016) (DOI:https://doi.org/10.18632/oncotarget.8931[2], (Bery et al., 2014) DOI:https://doi.org/10.1186/1559-0275-11-13[3], (Huang et al., 2018) DOI:https://doi.org/10.1097/IGC.0000000000001166[4]). Detailed peptidomic analysis of 26 ovarian cancer and 15 non-cancer samples of biological fluids (ascites and sera) were performed using TripleTOF 5600+ mass-spectrometer. Prior to LC-MS/MS analysis, peptides were extracted from biological fluids using anion exchange sorbent with subsequent peptide desorption from the surface of highly abundant proteins. In total, we identified 4874 peptides; 3123 peptides were specific for the ovarian cancer samples. The mass-spectrometry peptidomics data presented in this data article have been deposited to the ProteomeXchange Consortium (Deutsch et al., 2017) (DOI:https://doi.org/10.1093/nar/gkw936[5]) via the PRIDE partner repository with the dataset identifier PXD009382 and https://doi.org/10.6019/PXD009382, http://www.ebi.ac.uk/pride/archive/projects/PXD009382.
尽管对卵巢癌患者生物体液进行了大量蛋白质组学研究，但临床实践中仍缺乏灵敏的筛查方法（Kim等人，2016年）（DOI：https://doi.org/10.1111/cas.12987[1]）。与蛋白质相比，低分子量内源性肽更容易穿过内皮屏障，可能是更合适的生物标志物候选物（Meo等人，2016年）（DOI：https://doi.org/10.18632/oncotarget.8931[2]，（Bery等人，2014年）DOI：https://doi.org/10.1186/1559-0275-11-13[3]，（Huang等人，2018年）DOI：https://doi.org/10.1097/IGC.0000000000001166[4]）。使用TripleTOF 5600+质谱仪对26份卵巢癌生物体液样本（腹水和血清）以及15份非癌生物体液样本进行了详细的肽组学分析。在进行液相色谱-串联质谱（LC-MS/MS）分析之前，使用阴离子交换吸附剂从生物体液中提取肽，随后从高丰度蛋白质表面解吸肽。我们总共鉴定出4874种肽；其中3123种肽是卵巢癌样本特有的。本数据文章中呈现的质谱肽组学数据已通过PRIDE合作伙伴库存入蛋白质组交换联盟（Deutsch等人，2017年）（DOI：https://doi.org/10.1093/nar/gkw936[5]），数据集标识符为PXD009382，以及https://doi.org/10.6019/PXD009382，http://www.ebi.ac.uk/pride/archive/projects/PXD009382。
